Abstract:Objective: To determine the association of hypertension with Non-HDL Cholesterol (Non-HDL.C) among patients with type 2 diabetes mellitus. Study Design: Descriptive study.
“…Above all, the mean Non-HDL-c level was higher in hypertensives than in normotensive respondents. These ndings are generally in support of several studies that have reported a positive association between Non-HDL-c and hypertension, arterial stiffness and ischemic heart disease, and a cardiovascular event (de Oliveira Alvim et al, 2017;Zaka et al, 2020;Calling et al, 2021). Our…”
supporting
confidence: 91%
“…While several studies from different populations have reported that RC and Non-HDL-c (Zaka et al, 2020;Sun et al, 2022;Zheng et al, 2022) have more predictive power than LDL cholesterol in detecting CVD, very few studies have been done in sub-Saharan Africa on people with diabetes. The understanding of the role of obesity as a risk factor is still debated.…”
Type 2 diabetes mellitus (T2DM) continues to increase in incidence within the ageing population of the globe. Patients with T2DM have a 2-4 times higher risk of experiencing an adverse cardiovascular event than their non-diabetic counterparts. Total cholesterol, low-density lipoprotein (LDL), triglycerides and high-density lipoprotein (HDL) cholesterol levels have been the routine biomarkers for lipid-based cardiovascular disease diagnostic and prognostic decisions in clinical practice. Recent evidence elsewhere suggests remnant cholesterol (RC) and Non-HDL cholesterol (Non-HDL-c) can serve as biomarkers with a higher predictive power for cardiovascular disease (CVD) than the aforementioned routine ones. In our context, there is limited information on the suitability and superiority of these emerging biomarkers for the assessment of CVD risk in T2DM. The current study therefore sought to examine the relationship between RC and non-HDL-c for predicting CVD in T2DM patients in the context of the obesity paradox. Apart from adiponectin level which was lower (P < 0.05), overweight/obese respondents exhibited higher (P < 0.05) mean levels for all the measured indices. Insulin resistance was independently predicted (R2 = 0.951; adjusted R2 = 0.951; P < 0.001) by RC, duration and fasting plasma glucose. However, Non-HDL-c predicted CVD risk (AOR = 4.31; P <0.001), hypertension (AOR = 2.24; P <0.001), resistin (AOR = 2.14; P <0.001) and adiponectin (AOR = -2.24; P <0.001) levels. Our findings point to different mechanisms by which RC and non-HDL-c contribute to the development of CVD.
“…Above all, the mean Non-HDL-c level was higher in hypertensives than in normotensive respondents. These ndings are generally in support of several studies that have reported a positive association between Non-HDL-c and hypertension, arterial stiffness and ischemic heart disease, and a cardiovascular event (de Oliveira Alvim et al, 2017;Zaka et al, 2020;Calling et al, 2021). Our…”
supporting
confidence: 91%
“…While several studies from different populations have reported that RC and Non-HDL-c (Zaka et al, 2020;Sun et al, 2022;Zheng et al, 2022) have more predictive power than LDL cholesterol in detecting CVD, very few studies have been done in sub-Saharan Africa on people with diabetes. The understanding of the role of obesity as a risk factor is still debated.…”
Type 2 diabetes mellitus (T2DM) continues to increase in incidence within the ageing population of the globe. Patients with T2DM have a 2-4 times higher risk of experiencing an adverse cardiovascular event than their non-diabetic counterparts. Total cholesterol, low-density lipoprotein (LDL), triglycerides and high-density lipoprotein (HDL) cholesterol levels have been the routine biomarkers for lipid-based cardiovascular disease diagnostic and prognostic decisions in clinical practice. Recent evidence elsewhere suggests remnant cholesterol (RC) and Non-HDL cholesterol (Non-HDL-c) can serve as biomarkers with a higher predictive power for cardiovascular disease (CVD) than the aforementioned routine ones. In our context, there is limited information on the suitability and superiority of these emerging biomarkers for the assessment of CVD risk in T2DM. The current study therefore sought to examine the relationship between RC and non-HDL-c for predicting CVD in T2DM patients in the context of the obesity paradox. Apart from adiponectin level which was lower (P < 0.05), overweight/obese respondents exhibited higher (P < 0.05) mean levels for all the measured indices. Insulin resistance was independently predicted (R2 = 0.951; adjusted R2 = 0.951; P < 0.001) by RC, duration and fasting plasma glucose. However, Non-HDL-c predicted CVD risk (AOR = 4.31; P <0.001), hypertension (AOR = 2.24; P <0.001), resistin (AOR = 2.14; P <0.001) and adiponectin (AOR = -2.24; P <0.001) levels. Our findings point to different mechanisms by which RC and non-HDL-c contribute to the development of CVD.
“… 73 In contrast, Zaka and colleagues reported no significant difference in the mean of non‐HDL‐C among diabetic patients with hypertension and without hypertension (156.35 ± 38.52 mg/dL vs. 156.81 ± 45.82 mg/dL; p > .05). 74 The reason for these different findings may be due to the different enrolled populations in studies. We observed that women had higher levels of non‐HDL‐C compared to men.…”
This study assessed the association between atherosclerosis indices, serum uric acid to high‐density lipoprotein cholesterol ratio (UHR) and triglyceride‐glucose (TyG) index and the prevalence of hypertension among MASHAD cohort participants. In this cross‐sectional study, the participants were divided into hypertensive and non‐hypertensive subjects. The atherosclerosis indices, UHR and TyG index of the two groups were compared. Logistic regression analyses were used to determine the associations of these indices with hypertension in both sex. Receiver operating characteristic (ROC) curve analysis was used to establish the cut‐off values for differentiating hypertensive from non‐hypertensive subjects. p‐values < .05 were considered statistically significant. Data related to 9675 subjects (3035 hypertensive and 6640 non‐hypertensive) were analyzed. The mean values of atherosclerosis indices, UHR and TyG index were significantly higher (p < .001) in the hypertensives compared to non‐hypertensives. After adjustment for potential confounders, among men, the TyG index (OR = 1.360; 95% CI: 1.210–1.530; p < .001) remained an independent factor for hypertension. Among women, atherogenic index of plasma (OR = 1.005; 95% CI: 1.002–1.007; p < .001), UHR (OR = 1.043; 95% CI: 1.026–1.060; p < .001) and TyG index (OR = 1.519; 95% CI: 1.376–1.677; p < .001) remained independent factors for hypertension. ROC curve analysis revealed that compare to the other indices, TyG index had a better predictive value for hypertension in both sex, especially in women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.